Globus Medical, Inc. (GMED)
Market Cap | 5.57B |
Revenue (ttm) | 1.02B |
Net Income (ttm) | 190.17M |
Shares Out | 100.31M |
EPS (ttm) | 1.85 |
PE Ratio | 28.90 |
Forward PE | 32.26 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 214,917 |
Open | 54.80 |
Previous Close | 53.47 |
Day's Range | 54.55 - 55.27 |
52-Week Range | 50.92 - 81.78 |
Beta | 1.05 |
Analysts | Buy |
Price Target | 68.51 (+23.96%) |
Earnings Date | May 8, 2023 |
About GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspi... [Read more]
Financial Performance
In 2022, Globus Medical's revenue was $1.02 billion, an increase of 6.76% compared to the previous year's $958.10 million. Earnings were $190.17 million, an increase of 27.47%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for GMED stock is "Buy." The 12-month stock price forecast is $68.51, which is an increase of 23.96% from the latest price.
News

NUVASIVE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NuVasive, Inc. - NUVA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NuVasive, Inc. (...

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises
Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.

Globus Medical (GMED) Tops Q4 Earnings Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of 7.27% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical Reports Fourth Quarter and Full Year 2022 Results
AUDUBON, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year en...

Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NUVASIVE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NuVasive, Inc. - NUVA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NuVasive, Inc. (...

Top 5 Health Care Stocks That Could Blast Off This Month - Azenta (NASDAQ:AZTA), Amgen (NASDAQ:AMGN)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of NuVasive, Inc.
NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by NuVasive, Inc. (NASDAQ: NUVA) and its board of directors concerning the proposed acquisi...

GMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Globus Medical, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Globus Medical, Inc. (NYSE: GMED) and NuVasive, Inc. is fair to Globus shareholders. Un...

Globus Medical to Buy NuVasive in $3.1 Billion Deal
The implied price for NuVasive under terms of the deal is $57.72 a share.

NuVasive rallies while Globus Medical moves down after companies announce all-stock merger deal
Globus Medical GMED, -1.18% said Thursday it will pay 0.75 a share of its stock for each share of NuVasive NUVA, -2.41% stock in a deal that values NuVasive at about $3.1 billion or $57.72 a share. Gl...

Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care
Capitalizes on complementary global commercial organizations and accelerates Globus Medical's and NuVasive's globalization strategies to increase customer reach and deepen surgeon relationships Brings...

Globus Medical Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
AUDUBON, Pa., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ...

Here's Why Investors Should Retain Globus Medical (GMED) Stock
Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.

Globus Medical (GMED) Global Growth Strong Despite Margin Woe
Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market ...

Globus Medical Partners with the UK's NHS to Provide Hospitals with Surgical Robotic Navigation Technology
First Robotic Assisted Spine Surgeries Performed at Two NHS Trust Hospitals with Globus Medical's ExcelsiusGPS® First Robotic Assisted Spine Surgeries Performed at Two NHS Trust Hospitals with Globus ...

Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut
Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.

Globus Medical (GMED) Q3 Earnings Lag Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of -3.85% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical Reports Third Quarter 2022 Results
AUDUBON, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30...

Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical Schedules Third Quarter Earnings Release and Conference Call
AUDUBON, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September...

Here's Why Investors Should Retain Globus Medical (GMED) For Now
Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.

Globus Medical (GMED) Gains Market Share, Cost Woes Stay
Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.

Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.